ProCE Banner Activity

ATHENA-MONO: Phase III Trial of Maintenance Rucaparib vs Placebo After First-line Platinum-Based Chemotherapy in Advanced Ovarian Cancer

Slideset Download
Conference Coverage
First-line maintenance therapy with rucaparib significantly improved PFS vs placebo regardless of HRD status in patients with advanced ovarian cancer.

Released: June 14, 2022

Expiration: June 13, 2023

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen and Genmab